良性前列腺增生症和前列腺癌患者的血清与尿液前列腺特异性抗原比值
Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
作者信息
Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff J M, Seiter H, Schuff-Werner P
机构信息
Department of Urology, Faculty of Medicine, University of Rostock, Ernst-Heydemann-Str. 6, D-18057 Rostock, Germany.
出版信息
Anticancer Res. 2000 Nov-Dec;20(6D):4995-6.
BACKGROUND
Prostate-specific antigen (PSA) is the single most important tumor marker in early detection and monitoring of prostate cancer (CaP). However, routine analysis of serum PSA concentrations does not allow differentiation between CaP and prostatic diseases. The aim of the present study was to evaluate the usefulness of the serum-to-urinary PSA ratio in a clinical setting.
MATERIALS AND METHODS
In a retrospective clinical study, we determined serum and urine PSA concentrations in 48 patients with benign prostatic hyperplasia (BPH) and 57 patients with histologically confirmed CaP.
RESULTS
The serum-to-urinary PSA ratio is able to discriminate BPH from CaP.
CONCLUSIONS
Determination of the serum-to-urinary PSA ratio enhances the specificity of PSA in screening for CaP and monitoring of patients with CaP under androgen deprivation therapy.
背景
前列腺特异性抗原（PSA）是前列腺癌（CaP）早期检测和监测中最重要的单一肿瘤标志物。然而，血清PSA浓度的常规分析无法区分CaP和前列腺疾病。本研究的目的是评估血清与尿液PSA比值在临床环境中的实用性。
材料与方法
在一项回顾性临床研究中，我们测定了48例良性前列腺增生（BPH）患者和57例经组织学确诊的CaP患者的血清和尿液PSA浓度。
结果
血清与尿液PSA比值能够区分BPH和CaP。
结论
测定血清与尿液PSA比值可提高PSA在CaP筛查以及雄激素剥夺治疗下CaP患者监测中的特异性。
Zotero 插件